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Abstract
Background: Each year, worldwide about 530,000 women die from causes related to pregnancy and childbirth. Of the 
deaths 99% are in low and middle income countries. Obstetric haemorrhage is the leading cause of maternal mortality, 
most occurring in the postpartum period. Systemic antifibrinolytic agents are widely used in surgery to prevent clot 
breakdown (fibrinolysis) in order to reduce surgical blood loss. At present there is little reliable evidence from 
randomised trials on the effectiveness of tranexamic acid in the treatment of postpartum haemorrhage.
Methods: The Trial aims to determine the effect of early administration of tranexamic acid on mortality, hysterectomy 
and other morbidities (surgical interventions, blood transfusion, risk of non-fatal vascular events) in women with 
clinically diagnosed postpartum haemorrhage. The use of health services and safety, especially thromboembolic effect, 
on breastfed babies will also be assessed. The trial will be a large, pragmatic, randomised, double blind, placebo 
controlled trial among 15,000 women with a clinical diagnosis of postpartum haemorrhage. All legally adult women 
with clinically diagnosed postpartum haemorrhage following vaginal delivery of a baby or caesarean section will 
potentially be eligible. The fundamental eligibility criterion is the responsible clinician's 'uncertainty' as to whether or 
not to use an antifibrinolytic agent in a particular woman with postpartum haemorrhage. Treatment will entail a dose 
of tranexamic acid (1 gram by intravenous injection) or placebo (sodium chloride 0.9%) will be given as soon as 
possible after randomisation. A second dose may be given if after 30 minutes bleeding continues, or if it stops and 
restarts within 24 hours after the first dose.
The main analyses will be on an 'intention to treat' basis, irrespective of whether the allocated treatment was
received or not. Subgroup analyses for the primary outcome will be based on type of delivery; administration or not
of prophylactic uterotonics; and on whether the clinical decision to consider trial entry was based primarily on
estimated blood loss alone or on haemodynamic instability. A study with 15,000 women will have over 90% power to
detect a 25% reduction from 4% to 3% in the primary endpoint of mortality or hysterectomy.
Trial registration: Current Controlled Trials: ISRCTN76912190 and Clinicaltrials.gov ID: NCT00872469
Background
Each year, worldwide, about 530,000 women die from
causes related to pregnancy and childbirth. Nearly all
(99%) of these deaths are in low and middle income coun-
tries[1]. Haemorrhage, which usually occurs in the post-
partum period, is responsible for between one quarter
and one third of obstetric deaths[2]. Postpartum haemor-
rhage (PPH) is commonly defined as blood loss of ≥ 500
mL after vaginal delivery of a baby, or ≥ 1000 mL after
caesarean section. However, these thresholds do not take
into account pre-existing health status, and blood loss of
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as little as 200 mL can be life-threatening for a woman
with severe anaemia or cardiac disease[3].
Of the 14 million women who have PPH each year,
about 2% die, with an average interval from onset of
bleeding to death of 2 to 4 hours[2]. Although many
deaths from PPH occur outside healthcare facilities, a sig-
nificant number occur in hospital, where effective emer-
gency care has the potential to save lives [4,5]. PPH is also
an important cause of maternal mortality in high income
countries, accounting for about 13% of maternal
deaths[6].
PPH also causes hospital morbidity. Many women
require blood transfusion which sometimes can transmit
blood borne viral infections. Approximately 1% of women
with spontaneous vaginal deliveries require transfusion,
but the figure increases to 5% or 6% for women with
instrumental deliveries or caesarean sections [7]. The risk
of infection from transfused blood is considerably higher
in countries that do not screen all blood for transfu-
sion[8]. In high income countries the risk of transfusion
transmitted infection is low, but adverse reactions related
to blood transfusion are common[9].
Severe anaemia is a common consequence of PPH and
affects about 11% of the 14 million women with PPH each
year[10]. Severe anaemia can cause disabling fatigue and
seriously reduce a woman's capacity to look after her chil-
dren and to work[11]. Systemic antifibrinolytic agents are
widely used in surgery to prevent clot breakdown (fibrin-
olysis) in order to reduce surgical blood loss. A systematic
review of randomised controlled trials of antifibrinolytic
agents in surgical patients identified 211 randomised
controlled trials including 20,781 randomised partici-
pants. The results show that tranexamic acid (TXA)
reduces the risk of blood transfusion by a relative 39%
(RR = 0.61, 95% CI 0.54 to 0.69). In all patients, TXA
reduces transfused volume by 1.1 units (95% CI 0.64 to
1.59). TXA may also reduce the need for re-operation due
to bleeding (RR = 0.67, 95% CI 0.41 to 1.09). There was no
evidence of an increased risk of thrombotic events[12].
TXA significantly reduces uterine blood loss in women
with menorrhagia and is "recommended for consider-
ation" as a treatment in intractable postpartum haemor-
rhage in the UK[13]. However, at present there is little
reliable evidence from randomised trials on the effective-
ness of TXA in the treatment of PPH. A systematic
review of randomised trials of TXA in PPH conducted by
the investigators identified three trials of the prophylactic
use of TXA, including a total of 460 participants[14].
Although there was a statistically significant reduction in
average postpartum blood loss in women treated with
TXA [weighted mean reduction of approximately 100
mL] the quality of the trials was poor. None had adequate
allocation concealment and even in aggregate the trials
were too small to assess the effects of TXA on the clini-
cally important end points of mortality, hysterectomy and
thrombotic side effects. The most recently updated PPH
treatment guidelines prepared by the World Health Orga-
nization (WHO) state that TXA may be used in the treat-
ment of PPH if other measures fail, but points out that
the quality of evidence on which this recommendation is
based is low and recommends that further clinical trials
of TXA in PPH are conducted.
Need for a trial
The WOMAN Trial will provide a reliable scientific basis
for recommendations as to whether or not tranexamic
acid should be used in the treatment of PPH. If TXA
reduces mortality in women with PPH, this would be of
considerable significance worldwide. There is a global
commitment to the Millennium Development Goal
(MDG) of reducing maternal deaths by three-quarters by
the year 2015, a commitment that requires a reduction of
the maternal mortality ratio by 5.5% each year. Because
maternal haemorrhage accounts for over a quarter of
deaths, an effective treatment for PPH would contribute
importantly to the MDG of reducing maternal mortality.
TXA might also reduce the need for hysterectomy,
decrease the risk of anaemia and avoid the need for blood
transfusion. Blood is a scarce resource in many countries
with a risk of transfusion transmitted infections. If TXA
was effective in the hospital setting, further research
could be conducted to evaluate its use in the community,
possibly including the use of oral rather than intravenous
administration.
The results of this trial will be disseminated by publica-
tion in peer reviewed medical journals, conference pre-
sentations, and in an updated version of the Cochrane
systematic review of treatments for postpartum bleeding.
There is evidence that hospitals participating in multi-
centre trials are more likely to implement the trial
results[15]. For this reason, a large international multi-
centre trial like the WOMAN trial can be expected to
have a substantial impact on clinical practice. The large
network of collaborating sites will ensure that the results
are disseminated worldwide.
Tranexamic acid and its effect on bleeding
In the haemostatic process, coagulation occurs rapidly at
the site of a damaged vessel building a tight net of fibrin,
while at the same time, the fibrinolytic system removes
the fibrin deposits that could cause permanent vascular
occlusion once vascular repair has taken place[16]. The
coagulation and fibrinolytic system are believed to be in a
state of dynamic balance which maintains an intact vas-
cular system. Tranexamic acid is a potent antifibrinolytic
agent that exerts its effect by blocking lysine binding sites
on plasminogen molecules and has the potential to
enhance the effectiveness of the patient's own haemo-Shakur et al. Trials 2010, 11:40
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static mechanisms. Consequently, clot breakdown
(fibrinolysis) is inhibited and excessive or recurrent
bleeding is reduced.
During delivery, when the placenta separates from the
uterine wall, a sequence of physiologic and haemostatic
changes occur that reduce bleeding: strong myometrial
contractions, increased platelet activity, a massive release
of coagulant factors and a parallel increase in the fibrin-
olytic activity[17]. As a result, there is a theoretical ratio-
nale for the use of antifibrinolytic agents in the treatment
of postpartum haemorrhage[12,18,19].
Potential side effects of tranexamic acid
As TXA inhibits the breakdown of fibrin deposits already
formed, it might theoretically increase the risk of throm-
boembolism. However, the systematic review of TXA in
surgery did not show statistically significant increases in
the risks of any of the thromboembolic events assessed
(Table 1)[20].
During pregnancy, women have an increased risk of
thromboembolic events, compared with non-pregnant
women. The absolute risk of symptomatic venous throm-
bosis during pregnancy has been estimated to be between
0.5 and 3.0 per 1,000 women based on studies using
radiographic documentation [21-23]. Studies using
objective criteria for diagnosis have found that ante-par-
tum deep vein thrombosis (DVT) is as common as post-
partum thrombosis and occurs with equal frequency in
all three trimesters[21].
A population-based cohort study estimated an inci-
dence of thromboembolic events to be 200 per 100,000
woman-years[24]. DVT was three times more common
than pulmonary embolism and thromboembolic events
were five times more likely in the postpartum period than
during the pregnancy. This was particularly evident with
pulmonary embolism which was 15 times more likely to
oc cur  i n t he  pos t pa rt um  pe riod t ha n during  t h e pr eg-
n a n c y .  T h r o m b o e m b o l i c  e v e n t s  w i l l  b e  c o l l e c t e d  r o u -
tinely as part of the data collection process for this trial.
TXA passes into breast milk in very low concentra-
tions, approximately one hundredth of the concentration
in the maternal blood. An antifibrinolytic effect in the
infant is very unlikely at this low concentration[25]. The
thromboembolic effects on breastfed babies will be
assessed in this trial.
TXA is not a new drug and is generally well tolerated.
Adverse events are uncommon and usually manifest as
nausea or diarrhoea, or occasionally as orthostatic reac-
tions[12].
Objective
The WOMAN trial will provide reliable evidence as to
whether the antifibrinolytic agent tranexamic acid
reduces mortality, hysterectomy and other morbidities in
women with clinically diagnosed postpartum haemor-
rhage. Thromboembolic effects on breastfed babies will
be assessed.
Methods, design, discussion
Overview
This trial is a large, pragmatic, randomised, double blind,
placebo controlled trial to quantify the effects of the early
administration of tranexamic acid on death, hysterec-
tomy and other relevant outcomes. 15,000 adult women,
who have clinically diagnosed postpartum haemorrhage
and who fulfil the eligibility criteria, will be randomised
to receive either TXA or placebo. The eligibility criteria
are based on the uncertainty principle.
Pragmatic design and the uncertainty principle
The pragmatic design will allow us to find out how effec-
tive the treatment actually is in routine everyday practice.
The eligibility criteria are based on the uncertainty prin-
ciple. This approach to trial eligibility is well estab-
lished[26]. A patient can be enrolled if, and only if, the
responsible clinician is substantially uncertain as to
which of the trial treatments would be most appropriate
for that particular woman (see graph 1). A woman should
not be enrolled if the responsible clinician or the woman
(or her representative) are for any medical or non-medi-
cal reasons reasonably certain that one of the treatments
that might be allocated would be inappropriate for this
particular individual (in comparison with either no treat-
ment or some other treatment that could be offered to
the patient in or outside the trial). Using the uncertainty
principle should allow the process of this trial to be closer
to what is appropriate in normal medical practice. Clini-
cians, women and their representatives will be provided
with information about the trial treatment to assist them
in their judgement.
Randomisation
Women eligible for inclusion should be randomised, and
the study treatment started, as soon as possible. The
Entry form (see Additional file 1, Form 1: Entry form) will
be used to assess eligibility and collect baseline informa-
tion. The next consecutively numbered treatment pack,
taken from a box of eight packs, should be chosen. Once a
patient has been randomised, the outcome in hospital
needs to be collected even if the trial treatment is inter-
rupted or is not actually given.
Table 1: Effect of TXA
Events RR 95% CI
Myocardial infarction 0.96 0.48-1.90
Stroke 1.25 0.47-3.31
Deep venous thrombosis 0.77 0.37-1.61
Renal failure 0.73 0.16-3.32Shakur et al. Trials 2010, 11:40
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Follow-up
No extra tests are required for the trial but a short Out-
come form (see Additional file 2, Form 2: Outcome form)
must be completed directly from the medical records six
weeks (42 days) after randomisation or on discharge from
the randomising hospital or on death (whichever occurs
first). Any adverse events which become known to the
investigator will be reported up to 42 days after randomi-
sation.
Settings
The pragmatic nature of this trial will allow for the
recruitment of women from a wide variety of health care
facilities. Participating hospitals or maternal health facili-
ties will be selected from high, middle and low income
countries. Eligible women may have delivered their
babies at the participating hospital or may have delivered
outside the participating hospital and been admitted fol-
lowing the delivery of a baby. There is no limit to the
maximum number of women to be recruited at each site.
Number of patients needed
Two main factors determine the number of patients
needed in a trial. These are the estimated event rate and
size of the treatment effect.
Estimated event rate
Review of the literature and data from hospital reports
shows that there are wide variations in mortality after
PPH worldwide, varying from about 0.6% in the United
Kingdom to 2.6% in South Africa and 20% in some parts
of Africa. The frequency of occurrence of peripartum
hysterectomies also varies, from about 0.02% in the
United Kingdom to 2% in Nigeria or 14% in Congo-Braz-
zaville. Based on these ranges, a baseline event rate of
2.5% for mortality and 2.5% for hysterectomy might rea-
sonably be expected.
Sample size and size of treatment effect that should be 
detectable
Assuming a control group event rate of 2.5% for mortality
and 2.5% for hysterectomy with 1% of women having
both a hysterectomy and then dying, a study with 15,000
women would have over 90% power (two sided alpha =
5%) to detect a clinically important 25% reduction from
4% to 3% in the primary endpoint of mortality or hyster-
ectomy. A survey of baseline event rates among hospitals
that have expressed interest in taking part shows that
baseline event rates of this magnitude are realistic and
that higher baseline event rates might reasonably be
expected. Experience from the CRASH-1 and CRASH-2
clinical trials suggests that the anticipated rates of loss to
follow-up (less than 1%) would not impact importantly
on study power.
Recruitment of collaborating investigators
The trial will recruit collaborating sites from all countries
worldwide and will continue to add sites to ensure the
sample size is achieved. Suitable collaborating sites and
investigators will be assessed on the level of obstetric ser-
vice they provide and their ability to conduct the trial. In
advance of the trial starting at a site the Principal Investi-
gator must agree to adhere to Good Clinical Practice
Guidelines and all relevant regulations in their country. In
addition, all relevant regulatory and ethics approvals will
need to be in place.
Eligibility
Immediately after delivery of the baby/ies, all usual care
should be given for the prevention of PPH. Some bleed-
ing is expected after delivery. However, if bleeding con-
tinues and a diagnosis of PPH is made, all usual
treatments should be given and at the same time the
assessment for inclusion in the trial should be made. It is
important to consider inclusion as early as possible.
Inclusion criteria
All legally adult women with clinically diagnosed post-
partum haemorrhage following vaginal delivery of a baby
or caesarean section; women may have delivered their
babies at a participating hospital or outside a participat-
ing hospital, with hospital admission following delivery:
• where the responsible clinician is substantially uncer-
tain as to whether or not to use TXA
• when consent has been given according to approved
procedures
The clinical diagnosis of PPH may be based on any of
the following:
• estimated blood loss after vaginal delivery of a baby >
500 mL OR
• >1000 mL from caesarean section OR
• estimated blood loss enough to compromise the hae-
modynamic status of the woman
Exclusion criteria
• Women for whom the responsible clinician considers
there is a clear indication for TXA should not be ran-
domised.
• Women for whom the responsible clinician considers
there is a clear contraindication for TXA should not be
randomised (e.g. a known thromboembolic event during
pregnancy).
The fundamental eligibility criterion is the responsible
clinician's 'uncertainty' as to whether or not to use an
antifibrinolytic agent in a particular woman with postpar-
tum haemorrhage.
The TXA summary of product characteristics [25] and
an Investigator's Brochure will be provided to investiga-
tors to ensure they have adequate information when con-Shakur et al. Trials 2010, 11:40
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sidering the risk-benefit and the appropriateness of the
trial for each woman (Figure 1).
Consent and ethical considerations
This trial will be carried out worldwide and will include
women soon after delivery of a baby. Postpartum haem-
orrhage is an emergency situation and clinical activities
will be directed towards the provision of emergency care.
Eligible women have a life threatening condition. Further-
more, their physical, mental and emotional state may be
altered as a result of their blood loss or labour pains or by
drugs administered during the labour. The consent pro-
cess in this situation requires careful consideration bear-
ing in mind applicable regulatory requirements,
adherence to ICH-GCP and the requirements in the Dec-
laration of Helsinki.
Advance Information
The majority of women deliver without complications
and it would not be in the best interest of all pregnant
women to cause undue concern by providing detailed
information about this trial in the antenatal/delivery
period. Also, it is not possible to identify in advance those
women who will go on to develop PPH, and obtain
advance consent. Therefore, where possible, a summary
of the trial information will be provided to pregnant
w o m e n  ( s e e  A d d i t i o n a l  f i l e  3 ,  F o r m  3 :  B r i e f  a n t e n a t a l
information leaflet). Refusal to be considered for partic-
ipation will be documented in the woman's medical
records and her decision respected. Following delivery
of her baby, and once a woman has been diagnosed with
PPH, a critical clinical emergency situation exists. The
risk of death is highest early after delivery. The process
by which information will be given and consent
obtained will depend on the need for urgent clinical
intervention and her physical, mental and emotional
state. Also, the availability and ability of a personal rep-
resentative to make a decision on the woman's behalf
will have to be taken into consideration. The approach
which will allow the woman to have the most input into
the decision making process without endangering her
life will be utilised:
Figure 1 Eligibility graph.
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a) The woman is fully competent
The woman will be approached with the agreement of the
primary carer (the midwife or doctor) at the time of diag-
nosis. Factors which may impair her decision making
process including pain, altered level of consciousness due
to drugs given and degree of blood loss, will be taken into
consideration. An Information Sheet (see Additional file
4, Form 4: Information sheet for the woman and her rep-
resentative) will be provided and the study will be dis-
cussed with her and a written consent obtained (see
Additional file 5, Form 5: Patient consent form). If the
woman is unable to read or write, then the information
sheet may be read to her and she may then mark the con-
sent form with either a cross or thumbprint. In this event,
a witness NOT associated with the trial, must provide a
full signature confirming the mark.
b) The woman's mental capacity is impaired and either a 
Personal or Professional representative is available
Information should be given to the woman taking her
level of mental impairment into consideration. Oral
refusal by the woman should be respected and she should
not be enrolled.
(1) If a Personal Representative (PeR) who is knowl-
edgeable about the woman's values and beliefs is avail-
able, an Information Sheet will be provided. Opportunity
for questions should be given and written consent
obtained. If the PeR is unable to read or write, then the
information sheet may be read to him/her and a mark
with either a cross or thumbprint made on the consent
form (see Additional file 6, Form 6: Representative con-
sent form). In this event, a witness NOT associated with
the trial, must provide a full signature confirming the
mark.
(2) If a Personal Representative is not available and the
woman is unable to provide valid informed consent, then
an independent doctor/midwife/other site staff allowed
to fulfil this role (ideally the primary carer if s/he is not
part of the trial team) may be asked to consent as a Pro-
fessional Representative (PrR). Informed consent given
by a representative shall represent the woman's presumed
will.
(3) The woman's mental capacity is impaired and nei-
ther a Personal nor Professional representative is avail-
able: In situations where the woman is facing a clinical
emergency and no PeR/PrR is available, the investigator
and ONE independent person (doctor or midwife) who is
not participating in this trial may enrol the woman into
the trial by certifying in writing in the woman's medical
records that:
• the woman is facing a life-threatening postpartum
haemorrhage;
• the woman is unable to give her consent as a result
of her medical condition;
• it is not feasible to contact the woman's PeR/PrR to
obtain consent within the window period; and
• neither the woman nor the woman's PeR/PrR nor
any member of the family has informed the investiga-
tor of any objections to the woman being used as a
participant in this trial.
For women enrolled under such emergency consent
procedure, the woman or her PeR or PrR should be
i n f o r m e d  a b o u t  t h e  t r i a l  a s  s o o n  a s  i t  i s  p o s s i b l e  a n d
asked to consent for continuation of any trial procedure.
The requirements of the relevant ethics committee will
be adhered to at all times (Figure 2).
Randomisation
Randomisation codes will be generated and secured by an
independent statistical consultant from Sealed Envelope
Ltd (UK). The codes will be made available to Brecon
Pharmaceuticals Limited (UK) explicitly for the treat-
ment packs to be created in accordance with the ran-
domisation list. Eligibility will be determined from the
routinely collected clinical information and no trial-spe-
cific tests are required. Women eligible for inclusion
should be randomised to receive either active
(tranexamic acid) or placebo (sodium chloride 0.9%)
treatment and the trial treatment started as soon as possi-
ble.
Baseline information will be collected on the trial entry
form and the next lowest consecutively numbered pack
will be taken from a box of eight treatment packs. When
the treatment ampoule is confirmed as being intact, at
this point the patient is considered to be randomised
onto the trial. The entry form data will be sent to the Trial
Coordinating Centre as soon as possible. Once a patient
has been randomised, the outcome of the woman should
be obtained even if the trial treatment is interrupted or is
not actually given.
Treatment
Tranexamic acid will be compared with matching placebo
(sodium chloride 0.9%).
Dose selection
In randomised trials of antifibrinolytic agents in surgery,
TXA dose regimens vary widely. Loading doses range
from 2.5 mg/kg to 100 mg/kg and maintenance doses
from 0.25 mg/kg/hour to 4 mg/kg/hour given over peri-
ods of one to twelve hours. Studies examining the impact
of different doses of tranexamic acid on bleeding and
transfusion requirements showed no significant differ-
ences between a high dose and a low dose. Studies in car-
diac surgery have shown that a 10 mg/kg initial dose of
TXA followed by an infusion of 1 mg/kg/hour produces
plasma concentrations sufficient to inhibit fibrinolysis in
vitro. Horrow et al (1995) examined the dose-response
relationship of TXA and concluded that 10 mg/kg fol-Shakur et al. Trials 2010, 11:40
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lowed by 1 mg/kg/hour decreases bleeding in cardiac sur-
gery, but larger doses did not provide any additional
haemostatic benefit[27]. Trials of the use of TXA for the
prevention of obstetric haemorrhage used TXA at a dose
of 1 gram without major complications[14]. In the emer-
gency situation, the administration of a fixed dose is more
practicable since weighing women with PPH would be
difficult. Therefore, a fixed dose of 1 gram of TXA ini-
tially followed by 1 gram if bleeding continues, which is
within the dose range which has been shown to inhibit
fibrinolysis and provide haemostatic benefit, has been
selected for the WOMAN trial. On the basis of experi-
ence in surgery, the dose selected would be efficacious for
larger patients (>100 kg) but also safe in smaller patients
(<50 kg), as the estimated dose/kg that the patients in the
latter group would receive has been applied in other trials
without significant adverse effects.
Drug manufacture, blinding and supply of trial treatment
The active trial drug tranexamic acid (Cyklokapron®
Injection) will be purchased on the open market in the
UK. TXA is manufactured by Pfizer Ltd under Marketing
Authorisation Number: PL 00032/0314. The Marketing
Authorisation guarantees that the product has been man-
ufactured and released in accordance with the United
Kingdom's Good Manufacturing Regulations.
Placebo (sodium chloride 0.9%) will be manufactured
specially to match the tranexamic acid by South Devon
Healthcare NHS Trust, Kemmings Close, Paignton,
Devon, TQ4 7TW, under UK Manufacturer's authorisa-
tion Number: MS13079/MA(IMP) 13079.
Ampoules and packaging will be identical in appear-
ance. The blinding process and first stage Qualified Per-
son (QP) release will be done by Brecon Pharmaceuticals
Limited, Wye Valley Business Park, Hay-on-Wye, Here-
ford HR3 5PG, under UK Manufacturer's authorisation
Number MIA 11724/MIA IMP 11724. The blinding pro-
cess will involve complete removal of the original manu-
facturer's label and replacement with the clinical trial
label bearing the randomisation number which will be
used as the pack identification. Other pack label text will
be identical for both TXA and placebo treatments and
wi l l  be  i n  c o m p l ia n c e  wi t h  r eq u i r e m e n ts  f o r  i n v e s t i ga -
tional medicinal products. Treatment packs containing
TXA and placebo will be packed in balanced blocks of 8
(4 TXA:4 Placebo) into a box in random order . Brecon
Figure 2 Consent procedure diagram.
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Pharmaceuticals Limited will also be responsible for
maintaining the Product Specification File (PSF) until
final database lock and unblinding of the trial data. Qual-
ity control checks to assure blinding process will be per-
formed on a random sample of final QP released drug
packs. High Performance Liquid Chromatography analy-
ses (HPLC) separation of known tranexamic acid will be
assessed against blinded samples to confirm which
ampoule contains the placebo and active treatments. The
tested samples will be unblinded to assure accuracy of
blinding. The Trials Coordinating Centre (TCC) will be
responsible for assuring all relevant approvals are avail-
able at the TCC before release of the trial treatment to a
site.
Administration of trial treatment
Each treatment pack will contain:
• 4 × 500 mg ampoules of tranexamic acid or placebo
• 2 × sterile 10 mL syringe and 21FG needle
• Stickers (for attaching to data forms and patient med-
ical records)
Dose 1
2 ampoules = 1 gram - to be administered by intravenous
injection at an approximate rate of 1 mL/minute to all
randomised women as soon as possible after randomisa-
tion.
Dose 2
2 ampoules = 1 gram - If after 30 minutes bleeding con-
tinues, or if it stops and restarts within the 24 hours after
the first dose, a second dose may be given. To be adminis-
tered by intravenous injection at an approximate rate of 1
mL/minute. The trial treatment injections should not be
mixed with blood for transfusion, or infusion solutions
containing penicillin or mannitol.
Other treatments for postpartum haemorrhage
There is a wide spectrum of first and second line treat-
ments of postpartum haemorrhage. As the trial will be
conducted worldwide, each participating site should fol-
low its own clinical guidelines for the treatment of post-
partum haemorrhage. Information on other treatments
given will be collected on the outcome form. Tranexamic
acid or placebo would be an additional treatment to the
routine management of postpartum haemorrhage.
Adverse events (AE)
TXA has a well documented safety profile. No increase
in thromboembolic risks associated with its use has
been shown to date. However, as discussed in Section
1.3 an expected complication of pregnancy is an
increased risk of thromboembolic events. This trial will
collect data on all thromboembolic events as secondary
outcomes, and all such events are routinely reported to
the independent data monitoring committee (DMC) for
unblinded review.
Definitions
Adverse event (AE)
Any untoward medical occurrence affecting a trial partic-
ipant during the course of a clinical trial.
Serious Adverse Event (SAE)
A serious adverse event (experience) is any untoward
medical occurrence that at any dose results in death; is
life-threatening; requires inpatient hospitalisation or pro-
longation of existing hospitalisation; results in persistent
or significant disability/incapacity; or is a congenital
anomaly/birth defect.
Adverse Reaction (AR)
An adverse event when there is at least a possibility that it
is causally linked to a trial drug or intervention.
Serious Adverse Reaction (SAR)
SAE that is thought to be causally linked to a trial drug or
intervention.
Suspected Unexpected Serious Adverse Reaction (SUSAR)
An unexpected occurrence of a SAR; there need only be
an index of suspicion that the event is a previously unre-
ported reaction to a trial drug or a previously reported
but exaggerated or unexpectedly frequent adverse drug
reaction.
Reporting of Adverse Events for this trial
Death, life-threatening complications and prolonged hos-
pital stay are pre-specified outcomes to be reported in
this trial and also to the independent data monitoring
committee. This clinical trial is being conducted in a crit-
ical emergency condition, using a drug in common use. It
is important to consider the natural history of the critical
medical event affecting each woman enrolled, the
expected complications of this event and the relevance of
the complications to TXA.
Adverse events to be reported using an adverse event
reporting form will be limited to those NOT already
listed as primary or secondary outcomes, yet, which
might reasonably occur as a consequence of the trial
drug. Events that are part of the natural history of the pri-
mary event of PPH or expected complications of PPH
should not be reported as adverse events.
In addition, if a woman is discharged from the ran-
domising hospital before day 42 and is readmitted to hos-
pital, requires medical care for any reason or is known to
have died, an 'adverse event form' should be completed
irrespective of the cause. If a Serious Adverse Event
occurs, this should be logged by calling the Trial Coordi-
nating Centre Emergency Helpline and a written report
submitted within 24 hours. The TCC will coordinate the
reporting of all SAEs to all relevant Regulatory Agencies,
Ethics Committees and local investigators as per local
legal requirements.
Unblinding
In general there should be no need to unblind the allo-
cated treatment. If some contraindication to antifibrin-Shakur et al. Trials 2010, 11:40
http://www.trialsjournal.com/content/11/1/40
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olytic therapy develops after randomisation, e.g. clinical
evidence of thrombosis, the trial treatment should simply
be stopped and all usual standard care given. Unblinding
should be done only in those rare cases when the clinician
believes that clinical management depends importantly
upon knowledge of whether the patient received antifi-
brinolytic or placebo. In those few cases when urgent
unblinding is considered necessary, a 24-hour telephone
service will be available and details provided in the Inves-
tigator's Study File and wall posters. The caller will be
told whether the patient received antifibrinolytic or pla-
cebo. An unblinding report form should be completed by
the investigator.
Measures of outcome
After a patient has been randomised, outcome in hospital
will be collected even if the trial treatment is interrupted
or is not actually given. No extra tests are required but a
short single page Outcome Form will be completed 6
weeks (42 days) after randomisation, at discharge from
the randomising hospital or at death (whichever occurs
first).
Primary Outcome
The primary outcome is the proportion of women who
die or undergo hysterectomy. The primary cause of death
will be described.
Secondary outcomes
(a) Death.
(b) Surgical Interventions including hysterectomy;
brace suture (B-Lynch/Cho); selective arterial embolisa-
tion; laparotomy for other reasons; manual removal of
placenta; intrauterine tamponade (packing or gauzing the
uterine cavity, condom-catheter, any other method of
intrauterine tamponade); artery ligation, to achieve hae-
mostasis.
(c) Blood transfusion - blood or blood component units
transfused.
(d) Health Related Quality of life (HRQoL) will be mea-
sured by the proxy version of the EQ-5D at discharge
from the randomising hospital or in hospital at 42 days
after randomisation. The EQ-5D includes single item
measures of mobility, self-care, usual activities, pain/dis-
comfort and anxiety/depression. Each item is coded using
3 levels (1 = no problems; 2 = some problems; 3 = severe
problems). The instrument includes a global rating of
current health using a visual analogue scale (VAS) rang-
ing from 0 (worst imaginable) to 100 (best imaginable).
The EQ-5D is a generic measure of health status that pro-
vides a simple descriptive profile and a single index value
that can be used in the clinical and economic evaluation
of health care.
(e) Thromboembolic events (myocardial infarction,
strokes, pulmonary embolism, deep vein thrombosis).
(f) Medical events including renal failure, Adult Respi-
ratory Distress Syndrome, hypertensive disorders of
pregnancy (including HELLP Syndrome, eclampsia, tox-
aemia of pregnancy) and other adverse events reported.
(g) Length of stay at hospital/time spent at an intensive
care unit.
(h) Receipt of mechanical ventilation.
(i) Status of baby/ies: The health status of the baby/ies
will be ascertained and information collected on any
thromboembolic events in breastfed babies.
(j) Cost-effectiveness analysis: An economic analysis
will be relevant if TXA clearly demonstrates efficacy in
achieving its clinical aims. In this case, the study will be
undertaken in the form of a cost-effectiveness analysis
with the aim of estimating the incremental cost-effective-
ness ratio comparing the use of TXA with normal clinical
practice. Analysis will be based on adjusted life years
gained. A further analysis will explore the use of the EQ-
5D data to quality adjust survival. In this study, the eco-
nomic analysis is clearly bounded as virtually all signifi-
cant resource use will occur in the initial period of
hospitalisation. As such, neither a long-term resource
analysis nor an analysis of out of hospital costs will be
required. The trial use of TXA is likely to mirror its use in
normal clinical practice, hence the cost-effectiveness esti-
mated in the trial (adjusted for protocol driven costs) will
closely approximate cost-effectiveness in actual clinical
practice. Data on physical resource consumption (e.g.
length and nature of hospital stay) will be collected for
each patient and a common unit cost at a country level
will be applied. A sensitivity analysis will be undertaken
to assess the robustness of the economic analysis in
response to variations in key variables such as drug
prices. In all cases, the economic analysis will be inte-
grated with the clinical trial procedures to optimise effi-
ciency and minimise inconvenience to patients.
Data collection
This trial will be coordinated from LSHTM and con-
ducted in hospitals in low, middle and high income coun-
tries. Most recruitment will be in countries with high
rates of mortality and morbidity from postpartum haem-
orrhage. Data will be collected at each site by local inves-
tigators and transmitted to the TCC. Only data outlined
on the entry, outcome and adverse event forms will be
collected for this trial.
Relevant data on an entry form will be collected before
randomisation to assess eligibility and the form com-
pleted if randomised. The outcome form should be com-
pleted at death, discharge from the randomising hospital
or 6 weeks (42 days) after randomisation whichever
occurs first. This data should be collected from the rou-
tine medical records of the woman and her baby/ies as no
special tests are required.Shakur et al. Trials 2010, 11:40
http://www.trialsjournal.com/content/11/1/40
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If the woman (or her PeR or PrR) withdraws a previ-
ously given informed consent or refuses to consent for
continuation in the trial, or if the woman dies and no con-
sent is available from either a PeR/PrR, her data will be
handled as follows:
• Data collected to the point of withdrawal of consent
will be used as part of the intention to treat analysis.
• All relevant adverse events identified will be reported
as required to all relevant authorities.
To allow for variation in available technology for data
transfer a variety of methods will be used in this trial.
Data will be collected by the investigator on paper case
report forms (CRFs) and transmitted to the TCC either as
a paper form (by fax or email) or by entering the data
directly into the trial database. Data can also be transmit-
ted by entry onto electronic data files which can be
emailed or uploaded to the TCC secure web server. In
cases where electronic data files are used, data stored on
the investigator's computer(s) and data during transfer
will be secured by encryption. The data will be used in
accordance with local law and ethics committee approval.
Monitoring
GCP section 5.18.3 states in regard to monitoring, "The
determination of the extent and nature of monitoring
should be based on considerations such as the objective,
purpose, design, complexity, blinding, size and endpoints
of the trial. In general there is a need for on-site monitor-
ing, before, during, and after the trial; however in excep-
tional circumstances the sponsor may determine that
central monitoring in conjunction with procedures such as
investigators training and meetings, and extensive written
guidance can assure appropriate conduct of the trial in
accordance with GCP. Statistically controlled sampling
may be an acceptable method for selecting the data to be
verified."
This trial is a large, pragmatic, randomised placebo
controlled trial. The intervention (tranexamic acid) has
marketing authorisation in many countries and has been
in clinical use for over 40 years. Its safety profile is well
established and no significant serious adverse events
associated with its use have been identified. The trial will
routinely collect data on adverse events which may theo-
retically be associated with this product and the condi-
tion under investigation, and these will be reviewed
routinely by the independent Data Monitoring Commit-
tee (DMC). Other than consent, the administration of the
trial drug using a routine clinical procedure and collect-
ing routine clinical information from the medical records,
there are no complex procedures or interventions for the
participants or investigators in this trial. Clinical manage-
ment for underlying conditions will remain as per each
hospital's standard protocol. Based on these factors, the
probability of harm or injury (physical, psychological,
social or economic) occurring as a result of participation
in this research study has been assessed as low risk to
participants in each of these categories. Based on the low
r i s k s  a s s o c i a t e d  w i t h  t h i s  t r i a l ,  a  M o n i t o r i n g  P l a n  t o
assure appropriate conduct of the trial will be developed
which will incorporate 100% central monitoring in con-
junction with procedures such as investigator training
and meetings and written guidance. In addition, all data
will be subject to statistical monitoring and at least 10%
of data will be subjected to on-site monitoring. Investiga-
tors/institutions are required to provide direct access to
source data/documents for trial-related monitoring,
audits, ethics committee review and regulatory inspec-
tion. All trial related and source documents must be kept
for five years after the end of the trial.
End of trial for participants
The trial ends either at death, discharge, or six weeks
post-randomisation, whichever occurs first. If during the
treatment phase a woman develops an adverse event the
trial drug should be stopped, woman treated in line with
local procedures and then followed up.
The trial may be terminated early by the Trial Steering
Committee (TSC). The DMC may give advice/recom-
mendation for the early termination of the trial but the
TSC is responsible for the final decision.
Analysis
The main analyses will compare all those allocated antifi-
brinolytic treatment versus those allocated placebo, on an
'intention to treat' basis, irrespective of whether they
received the allocated treatment or not. Results will be
presented as appropriate effect estimates with a measure
of precision (95% confidence intervals). Subgroup analy-
ses for the primary outcome will be based on type of
delivery (vaginal or caesarean section); administration or
not of prophylactic uterotonics; and on whether the clini-
cal decision to consider trial entry was based primarily on
estimated blood loss alone or on haemodynamic instabil-
ity. Interaction test will be used to test whether the effect
of treatment (if any) differs across these subgroups.
Between-sites heterogeneity in effectiveness will be
explored. All analyses will be conducted in STATA. A
detailed Statistical Analysis Plan setting out full details of
the proposed analyses will be finalised before the trial
database is locked for final analysis.
Sponsorship and trial management
The WOMAN Trial is sponsored by the London School
of Hygiene & Tropical Medicine (LSHTM) and its
responsibilities coordinated by the Trial Coordinating
Centre (TCC). The TCC may delegate responsibilities to
third parties which will be outlined in relevant agree-
ments. The responsibilities of the TCC will be overseen
by the Trial Management Group.Shakur et al. Trials 2010, 11:40
http://www.trialsjournal.com/content/11/1/40
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Indemnity
LSHTM accepts responsibility attached to its sponsor-
ship of the trial and, as such, would be responsible for
claims for any non-negligent harm suffered by anyone as
a result of participating in this trial. The indemnity is
renewed on an annual basis and LSHTM assures that it
will continue renewal of the indemnity for the duration of
this trial.
Protocol development
The Protocol Committee consists of the following inves-
tigators who will be responsible for the development of
and agreeing to the final protocol. Subsequent changes to
the final Protocol will require the agreement of the Trial
Steering Committee.
• Chief investigator: Professor Ian Roberts
• Clinical experts: Professor Zarko Alfirevic, Dr Metin
Gülmezoglu, Professor Carine Ronsmans
• Trial management: Ms Haleema Shakur
• Statistician: Professor Diana Elbourne
Independent data monitoring committee (DMC)
• Professor Sir Iain Chalmers, James Lind Initiative,
Oxford, UK (Large scale randomised controlled trials;
Obstetric care).
• Professor Pisake Lumbiganon, Professor of Obstetrics
& Gynaecology; Convenor, Thai Cochrane Network; Fac-
ulty of Medicine, Khon Kaen University, Thailand
(Obstetric care).
• Dr Gilda Piaggio, Statistika Consultoria, São Paulo,
Brazil (Statistician, extensive experience of reproductive
health and research at the World Health Organization).
Mortality and severe morbidity is expected within the
target population. To provide protection for study partic-
ipants, an independent DMC has been appointed for this
trial to oversee the safety monitoring. The DMC will
review on a regular basis accumulating data from the
ongoing trial and advise the Trial Steering Committee
regarding the continuing safety of current participants
and those yet to be recruited, as well as reviewing the
validity and scientific merit of the trial.
The DMC composition, name, title and address of the
chairman and of each member, will be given in the DMC
Charter which will be in line with that proposed by the
DAMOCLES Study Group[28]. Membership includes
e x p e r t i s e  i n  t h e  r e l e v a n t  f i e l d  o f  s t u d y ,  s t a t i s t i c s  a n d
research study design. The DMC Charter includes, but is
not limited to, defining:
(a) the schedule and format of the DMC meetings
(b) the format for presentation of data
(c) the method and timing of providing interim reports
(d) stopping rules
Standard Operating Procedures
The Data Monitoring Committee (DMC) has the respon-
sibility for deciding whether, while randomisation is in
progress, the unblinded results (or the unblinded results
for a particular subgroup), should be revealed to the TSC.
The DMC Charter states that they will do this if, and only
if, two conditions are satisfied:
(1) the results provide proof beyond reasonable doubt
that treatment is on balance either definitely harmful or
definitely favourable for all, or for a particular category of,
participants in terms of the major outcome; (2) The
results, if revealed, would be expected to substantially
change the prescribing patterns of clinicians who are
already familiar with any other trial results that exist.
Ex a ct  c ri t e ria  f o r  " p r oo f  bey o n d  r eas o n a b l e  d o u b t "  a r e
not, and cannot be, specified by a purely mathematical
stopping rule, but they are strongly influenced by such
rules. DMC Charter is in agreement with the Peto-Hay-
bittle [29,30] stopping rule whereby an interim analysis of
major endpoint would generally need to involve a differ-
ence between treatment and control of at least three stan-
dard errors to justify premature disclosure. An interim
subgroup analysis would, of course, have to be even more
extreme to justify disclosure. This rule has the advantage
that the exact number and timing of interim analyses
need not be pre-specified. In summary, the stopping rules
require extreme differences to justify premature disclo-
sure and involve an appropriate combination of mathe-
matical stopping rules and scientific judgment.
Trial steering committee (TSC)
• Professor Adrian Grant (Chair), Director, Health Ser-
vices Research Unit, University of Aberdeen (Health Ser-
vices Research; Randomised Control Trials).
• Professor Ian Roberts, London School of Hygiene &
Tropical Medicine (Epidemiology; Randomised Control
Trials; Conduct of large scale international trials).
• Dr Metin Gülmezoglu, World Health Organization,
Geneva (Obstetrician; Coordinating Editor of the WHO
Reproductive Health Library; Randomised Control Tri-
als).
• Dr Kaosar Afsana, BRAC Health Programme, Bangla-
desh (Reproductive & Sexual Health & Rights; Rural and
Urban Maternal, Neonatal and Child Health Programme
in BRAC).
• Dr Oladapo Olayemi, University College Hospital,
Ibadan, Nigeria (Consultant Obstetrician; perspective on
obstetrics in a developing country).
• Professor Beverley Hunt, Kings College, London (Pro-
fessor of Thrombosis & Haemostasis, Randomised Con-
trol Trials).
The role of the TSC is to provide overall supervision of
the trial. In particular, the TSC will concentrate on the
progress of the trial, adherence to the protocol, patient
safety and consideration of new information. The TSC
m u s t  b e  i n  a g r e e m e n t  w i t h  t h e  f i n a l  P r o t o c o l  a n d ,
throughout the trial, will take responsibility for:Shakur et al. Trials 2010, 11:40
http://www.trialsjournal.com/content/11/1/40
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(a) major decisions such as a need to change the proto-
col for any reason
(b) monitoring and supervising the progress of the trial
(c) reviewing relevant information from other sources
(d) considering recommendations from the DMC
(e) informing and advising the Trial Management
Group on all aspects of the trial The steering committee
consists of experienced obstetric experts, clinical trialists
as well as a Reproductive & Sexual Health & Rights repre-
sentative. Face to face meetings will be held at regular
intervals determined by need, but no less than once a
year. A TSC Charter will be agreed at the first meeting
which will detail how it will conduct its business.
When outcome data are available for 1,000 trial partici-
pants, the TSC will review the rate of recruitment into
the trial and the overall event rates. The TSC will con-
sider the extent to which the rate of recruitment and the
event rates correspond to those anticipated before the
trial and will take whatever action is needed in light of
this information.
Collaborators' responsibilities
Coordination within each participating hospital will be
through a local Principal Investigator whose responsibil-
ity will be detailed in an agreement in advance of starting
the trial and will include:
• Ensure all necessary approvals are in place prior to
starting the trial
• Delegate trial related responsibilities only to suitably
trained and qualified personnel
• Train relevant medical and nursing staff who see
obstetric patients and ensure that they remain aware of
the state of the current knowledge, the trial and its proce-
dures (there are wall charts, pocket summaries and a set
of slides to assist with this)
• Agree to comply with the final trial protocol and any
relevant amendments
• Ensure that all women with postpartum haemorrhage
are considered promptly for the trial
• Ensure consent is obtained in line with local approved
procedures
• Ensure that the patient entry and outcome data are
completed and transmitted to the TCC in a timely man-
ner
• Ensure the Investigator's Study File is up-to-date and
complete
• Ensure all Adverse Events are reported promptly to
the TCC
• Accountability for trial treatments at their site
• Ensure the trial is conducted in accordance with ICH
GCP and fulfils all national and local regulatory require-
ments
• Allow access to source data for monitoring, audit and
inspection
• Be responsible for archiving all original trial docu-
ments including the data forms for five years after the end
of the trial
Trial management group (TMG) and trial coordinating 
centre (TCC) responsibilities
The Trial Management Group will consist of the Protocol
Committee members (Section 3.3) plus a trial manager,
data manager and trial administrator. The TCC will act
on behalf of the Sponsor and will be responsible to the
TMG to ensure that all Sponsor's responsibilities are car-
ried out. The responsibilities will include (but not limited
to):
• Report to the Trial Steering Committee
• Maintain the Trial Master File
• Identify trial sites
• Confirm all approvals are in place before release of the
trial treatment and the start of the trial at a site
• Provide training about the trial
• Provide study materials
• Data management centre
• 24-hour advice and unblinding service
• Give collaborators regular information about the
progress of the study
• Respond to any questions (e.g. from collaborators)
about the trial
• Ensure data security and quality and observe data
protection laws
• Safety reporting
• Ensure trial is conducted in accordance with the ICH
GCP
• Statistical analysis
• Publication of trial results
Contacting the TCC in an emergency
For urgent enquiries, adverse event reporting and
unblinding queries investigators can contact the 24-hour
telephone service provided by the TCC. A central tele-
phone number is given in the Investigator's Study File and
posters.
Publication and dissemination of results
All efforts will be made to ensure that the trial protocol
and results arising from the WOMAN trial are published
in an established peer-reviewed journal. At least one pub-
lication of the main trial results will be made. All publica-
tions will follow relevant external guidance such as the
'Uniform Requirements for Submission of Manuscripts to
Biomedical Journals' issued by the International Commit-
tee of Medical Journal Editors (ICMJE) (2008 update) and
the CONSORT statement [31,32]. Links to the publica-
tion will be provided in all applicable trial registers. Dis-
semination of results to patients will take place via the
media, trial website http://www.womantrial.lshtm.ac.uk/
and relevant patient organisations. Collaborating investi-Shakur et al. Trials 2010, 11:40
http://www.trialsjournal.com/content/11/1/40
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gators will play a vital role in disseminating the results to
colleagues and patients.
The success of the trial will be dependent entirely upon
the collaboration of midwives, nurses and doctors in the
participating hospitals and those who hold key responsi-
bility for the trial. Hence, the credit for the study will be
assigned to the key collaborator(s) from a participating
site as it is crucial that those taking credit for the work
have actually carried it out. The results of the trial will be
reported first to trial collaborators.
Financial support
LSHTM is funding the run-in costs for this trial and up to
2,000 patients' recruitment. Full funding is being sought
from public funding organisations. Funding for this trial
covers meetings and central organisational costs only.
Pfizer, the manufacturer of tranexamic acid, have pro-
vided the funding for the trial drug and placebo used for
this trial. The design and management of the study are
entirely independent of the manufacturers of tranexamic
acid, which is not a new product.
Large trials of such drugs, involving many hospitals, are
important for future patients, but are practicable only if
those collaborating in them do so without payment
(except for recompense of any minor local costs that may
arise). Agreement for repayment of local costs will be
made in advance.
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